The Korean Society for Neuro-Oncology (KSNO) Guideline for WHO Grade II Cerebral Gliomas in Adults: Version 2019.01
| العنوان: | The Korean Society for Neuro-Oncology (KSNO) Guideline for WHO Grade II Cerebral Gliomas in Adults: Version 2019.01 |
|---|---|
| المؤلفون: | Kim, Young Zoon, Kim, Chae-Yong, Wee, Chan Woo, Roh, Tae Hoon, Hong, Je Beom, Oh, Hyuk-Jin, Kang, Seok-Gu, Kang, Shin-Hyuk, Kong, Doo-Sik, Kim, Sung Hwan, Kim, Se-Hyuk, Kim, Se Hoon, Kim, Yu Jung, Kim, Eui Hyun, Kim, In Ah, Kim, Ho Sung, Park, Jae-Sung, Park, Hyun Jin, Song, Sang Woo, Sung, Kyoung Su, Yang, Seung Ho, Yoon, Wan-Soo, Yoon, Hong In, Lee, Jihae, Lee, Soon-Tae, Lee, Sea-Won, Lee, Youn Soo, Lim, Jaejoon, Chang, Jong Hee, Jung, Tae-Young, Jung, Hye Lim, Cho, Jae Ho, Choi, Seung Hong, Choi, Hyoung Soo, Lim, Do Hoon, Chung, Dong-Sup |
| المصدر: | Brain Tumor Research and Treatment |
| بيانات النشر: | The Korean Brain Tumor Society; The Korean Society for Neuro-Oncology; The Korean Society for Pediatric Neuro-Oncology, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | Practice, Korean Society for Neuro-Oncology, Grade II Gliomas, General Earth and Planetary Sciences, Original Article, Guideline, neoplasms, General Environmental Science, nervous system diseases |
| الوصف: | Background There was no practical guideline for the management of patients with central nervous system tumor in Korea for many years. Thus, the Korean Society for Neuro-Oncology (KSNO), a multidisciplinary academic society, has developed the guideline for glioblastoma. Subsequently, the KSNO guideline for World Health Organization (WHO) grade II cerebral glioma in adults is established. Methods The Working Group was composed of 35 multidisciplinary medical experts in Korea. References were identified by searching PubMed, MEDLINE, EMBASE, and Cochrane CENTRAL databases using specific and sensitive keywords as well as combinations of keywords regarding diffuse astrocytoma and oligodendroglioma of brain in adults. Results Whenever radiological feature suggests lower grade glioma, the maximal safe resection if feasible is recommended globally. After molecular and histological examinations, patients with diffuse astrocytoma, isocitrate dehydrogenase (IDH)-wildtype without molecular feature of glioblastoma should be primarily treated by standard brain radiotherapy and adjuvant temozolomide chemotherapy (Level III) while those with molecular feature of glioblastoma should be treated following the protocol for glioblastomas. In terms of patients with diffuse astrocytoma, IDH-mutant and oligodendroglioma (IDH-mutant and 1p19q codeletion), standard brain radiotherapy and adjuvant PCV (procarbazine+lomustine+vincristine) combination chemotherapy should be considered primarily for the high-risk group while observation with regular follow up should be considered for the low-risk group. Conclusion The KSNO's guideline recommends that WHO grade II gliomas should be treated by maximal safe resection, if feasible, followed by radiotherapy and/or chemotherapy according to molecular and histological features of tumors and clinical characteristics of patients. |
| اللغة: | English |
| تدمد: | 2288-2413 2288-2405 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6da4e12fd87f4b29748f102f1680eae9Test http://europepmc.org/articles/PMC6829081Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....6da4e12fd87f4b29748f102f1680eae9 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 22882413 22882405 |
|---|